(-)Deprenyl (Selegiline, Jumex,
Eldepryl, Movergan), a close structural relative of
phenylethylamine (PEA), is a drug with a unique pharmacological
spectrum. Whereas PEA and its long-lasting variants, the
amphetamines, are mixed-acting stimulants of the sympathetic
system in the brain, they primarily enhance the impulse
propagation generated release of catecholamines (catecholamine
activity enhancer, CAE, effect) and displace catecholamines in
higher concentration (catecholamine releasing effect). (-)Deprenyl
is the first CAE substance in clinical use devoid of catecholamine
releasing activity. (-)Deprenyl is a highly potent and selective,
irreversible inhibitor of B-type monoamine oxidase (MAO), a
predominantly glial enzyme in the brain. The activity of this
enzyme significantly increases with age. (-)Deprenyl, the first
selective inhibitor of MAO-B described in the literature, has
become a universally used research tool for selectively blocking
B-type MAO and is still the only selective MAO-B inhibitor in
world wide clinical use. In contrast to MAO inhibitors which
strongly potentiate the catecholamine releasing effect of tyramine,
(-)deprenyl inhibits it and is free of the 'cheese effect', which
makes it a safe drug. Because its lack of the catecholamine
releasing activity (-)deprenyl is devoid of amphetamine like
dependence capacity. Maintenance on (-)deprenyl selectively
enhances superoxide dismutase (SOD) and catalase activity in the
striatum and protects the nigrostriatal dopaminergic neurons from
selective neurotoxins (6-hydroxydopamine, MPTP, DSP-4). Maintenance of an animal on (-)deprenyl prevents the
characteristic age-related morphological changes in the
neuromelanin granules of the neurocytes in the substantia nigra.
Many other protective effects of (-)deprenyl, denoted as 'neuroprotective',
'trophiclike neurorescue', 'apoptosis reducing', etc, have been
described. All the protective actions of (-)deprenyl are thought
to be primarily related to the CAE effect of the drug. All in all,
(-)deprenyl increases the activity of the nigrostriatal
dopaminergic system and slows its age-related decline. Maintenance
of male rats on (-)deprenyl delays the age-related loss of their
capacity to ejaculate, slows the age-related decline of their
learning capacity and prolongs their life. Parkinsonian patients
on levodopa plus (-)deprenyl (10 mg daily) live significantly
longer than those on levodopa alone. Parkinsonian patients
maintained, after diagnosis, on (-)deprenyl, need levodopa
significantly later than their placebo-treated peers. Maintenance
on (-)deprenyl significantly improves the performance of patients
with Alzheimer's disease. It is concluded that patients developing
Parkinson's or Alzheimer's disease need to be treated daily with
10 mg (-)deprenyl from diagnosis until death, irrespective of
other medication. Because of the peculiar pharmacological spectrum
and safety of the drug it may be advisable to combat the
age-related decline of the nigrostriatal dopaminergic neurons in
man by taking 10-15 mg (-)deprenyl weekly during the
postdevelopmental phase of life. Prophylactic (-)deprenyl
medication may improve the quality of life in the latter decades,
delaying the time of natural death and decreasing the
susceptibility to age-related neurological diseases.
-
Deprenyl
is an effective antidepressant
-
Deprenyl
in treatment-resistant older depressive patients
-
Deprenyl
+ phenylalanine was beneficial in 90% of
depression patients
-
Deprenyl
antidepressant effects are by
means other than MAO-B inhibition
Deprenyl
treated rats were much more
sexually active
Deprenyl
enhances sexual performance and longevity
in rats
Deprenyl
may delay the deterioration of neurons during aging
Deprenyl the history of deprenyl
Deprenyl
decreases susceptibility to Parkinson's
& Alzheimer's disease
Deprenyl
restores IGF-1 to
youthful levels
Deprenyl
protects the vascular endothelium from
beta amyloid plaque
Deprenyl
reduces cocaine "high"
Deprenyl
prolongs animal lifespan by reducing oxidative damage to the brain
Deprenyl
may be useful in the treatment of
cocaine dependence
Deprenyl
increases the life span in Fischer
rats
Deprenyl
effects on short term memory in
young and aged dogs
Deprenyl
maintains sexual acitivity in old rats
Deprenyl
and Fluoxetine
(Prozac) do not interact in combination
Deprenyl
prolongs life
in elderly dogs
Deprenyl
has a cardiac
neuroprotective effect
Deprenyl
reduces oxidative stress and increases free radical elimination
-
Deprenyl
responses of forebrain neurons to
deprenyl
-
Deprenyl
Parkinson's and Alzheimer's patients need
10 mg of deprenyl daily
-
Deprenyl
inhibits tumor growth in rats with
mammary tumors
-
Deprenyl
slows the decline of sexual and learning performances in rats
-
Deprenyl
is ten times stronger than methamphetamine as a catecholaminergic
-
Deprenyl
shows favorable results in Tourette's syndrome and narcolepsy
-
Deprenyl
treated rats lived beyond the known maximum lifespan
-
Deprenyl
protects cells from the DNA damage
-
Deprenyl
may protect neurons from ischemic
or oxidative damage
-
Deprenyl
prolongs animal lifespan by reducing oxidative damage to the brain
-
Deprenyl
effects on cocaine-induced euphoria
-
Deprenyl
effects on
response to experimental cocaine administration
-
Deprenyl
Are metabolites of
deprenyl useful or harmful?
-
Deprenyl
slows the progression of Parkinson's disease
-
Deprenyl
suppresses excitotoxic damage in Parkinson's disease
-
Deprenyl
effect of deprenyl on arm movement in early Parkinson's
-
Deprenyl
effect
on cognitive functions in early Parkinson's
-
Deprenyl
prolongs the life span of Parkinsonian patients significantly
-
Deprenyl
depression
in Parkinson's disease
-
Deprenyl
increases the dopamine content of the nerve terminals
in Parkinson's
-
Deprenyl
improves visuo-motor control in
early Parkinsonism
-
Deprenyl
management of early Parkinson's disease
-
Deprenyl
delays the onset of
disability in Parkinsonian patients
-
Deprenyl
and tocopherol antioxidative therapy of
Parkinsonism
-
Deprenyl
slows the death of nigral neurons in Parkinson's
disease
-
Deprenyl
+ levodopa treated Parkinson's patients live longer
-
Deprenyl
stimulates biosynthesis of cytokines interleukin-1 & 6
-
Deprenyl
effect
of MAO-B inhibitors on MPP+ toxicity
-
Deprenyl
modulates the activity of catecholamine-sensitive neurons
-
Deprenyl
improves the performance of patients with
Alzheimer's disease
-
Deprenyl
for Alzheimer's disease
-
Deprenyl
MAO-B inhibitors in the treatment of Alzheimer's disease
-
Deprenyl
in
the treatment of Alzheimer's disease
-
Deprenyl
stimulates biosynthesis of cytokines interleukin-1 &
6
-
Deprenyl
and
age-related decline of the striatal dopaminergic system
-
Deprenyl
increases dopamine in the striatum of primates
-
Deprenyl
use
in treatment-resistant elderly depression patients
-
Deprenyl
protects against neurotoxins
-
Deprenyl
increased rat lifespan by 5%
Deprenyl
neuroprotective
action
Deprenyl
inhibition of human LDL
oxidation
Deprenyl
facilitates recovery after
stroke
Deprenyl
effects during smoking and short-term abstinence
